{
    "clinical_study": {
        "@rank": "1548", 
        "arm_group": [
            {
                "arm_group_label": "SIMBRINZA\u2122", 
                "arm_group_type": "Experimental", 
                "description": "Brinzolamide 1 %/Brimonidine 0.2% ophthalmic suspension. One drop three times a day (TID) in both eyes for 4 weeks."
            }, 
            {
                "arm_group_label": "Timolol Maleate 0.5%", 
                "arm_group_type": "Active Comparator", 
                "description": "Timolol Maleate 0.5%. One drop twice a day (BID) in both eyes for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period\n      using Simbrinza\u2122 topical ophthalmic suspension."
        }, 
        "brief_title": "Evaluation of Intraocular Pressure Using Simbrinza\u2122 in Patients With Open-Angle Glaucoma or Ocular Hypertension.", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Open-Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will consist of two phases.  Phase I is the Screening/Eligibility Phase, which\n      includes a Screening Visit during which the subject will washout of all other IOP-lowering\n      medications, followed by one Eligibility Visit. Only subjects meeting all requirements of\n      inclusion and exclusion criteria will be treated in the next phase.  Phase II is the\n      treatment phase, which includes visits at Week 2/Day 14 and Week 4/Day 30 (Exit Visit).\n      Both phases will require the subject to complete an overnight stay."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a clinical diagnosis of either open-angle glaucoma or ocular hypertension in\n             both eyes.\n\n          -  Have a mean IOP measurement in at least 1 eye greater than or equal to 21 and less\n             than 36 millimeters mercury (mmHg) at 8 AM during the Eligibility visit.\n\n          -  Ability to wash out previous IOP lowering medication and meet IOP entry criteria.\n\n          -  Willing and able to attend all study-related visits and be housed overnight at\n             clinical site for the study assessments.\n\n          -  Must sign an Informed Consent form.\n\n          -  Other protocol-specified inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential if pregnant, breastfeeding, or not using adequate\n             birth control.\n\n          -  Severe central visual field loss in either eye.\n\n          -  Cannot safely undergo the initial wash-out period discontinuing all IOP-lowering\n             ocular medication(s) for a minimum of 5 (\u00b11 day) to 28 (\u00b11 day) days prior to\n             Eligibility Visit 1.\n\n          -  Chronic, recurrent or severe inflammatory eye disease (e.g. scleritis, uveitis,\n             herpes keratitis).\n\n          -  Ocular trauma or ocular surgery within the past 6 months.\n\n          -  Ocular infection or ocular inflammation within the past 3 months.\n\n          -  Clinically significant or progressive retinal disease such as retinal degeneration,\n             diabetic retinopathy, or retinal detachment.\n\n          -  Best Corrected Visual Acuity (BCVA) score worse than approximately 20/80 Snellen.\n\n          -  Other ocular pathology, including severe dry eye, that may in the opinion of the\n             investigator preclude the administration of study medication.\n\n          -  Any abnormality preventing reliable measurement of IOP.\n\n          -  Any other conditions including severe illness which would make the patient, in the\n             opinion of the Investigator, unsuitable for the study.\n\n          -  Therapy with another investigational agent within 30 days prior to the Screening\n             Visit.\n\n          -  Any medical condition that would preclude the safe administration of a topical\n             beta-blocker.\n\n          -  Patients who cannot safely discontinue all glucocorticoids administered by any route.\n\n          -  Other protocol-specified exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "89", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978600", 
            "org_study_id": "M-13-037"
        }, 
        "intervention": [
            {
                "arm_group_label": "SIMBRINZA\u2122", 
                "description": "Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.", 
                "intervention_name": "Brinzolamide 1 %/Brimonidine 0.2% ophthalmic suspension", 
                "intervention_type": "Drug", 
                "other_name": "SIMBRINZA\u2122"
            }, 
            {
                "arm_group_label": "Timolol Maleate 0.5%", 
                "description": "Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.", 
                "intervention_name": "Timolol Maleate 0.5%", 
                "intervention_type": "Drug", 
                "other_name": [
                    "TIMOPTIC\u2122", 
                    "TIMOPTIC-XE\u2122", 
                    "BETIMOL\u2122", 
                    "TIMOLOL GEL-FORMING SOLUTION\u00ae", 
                    "ISTALOL\u2122"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Timolol", 
                "Brimonidine", 
                "Maleic acid", 
                "Brinzolamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Open-Angle Glaucoma", 
            "Ocular Hypertension", 
            "Simbrinza\u2122", 
            "Intraocular Pressure"
        ], 
        "lastchanged_date": "May 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Location"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1% /Brimonidine 0.2% Fixed Dose Combination Therapy", 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Danyel Carr, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Mean nocturnal IOP at Week 4", 
            "safety_issue": "No", 
            "time_frame": "Week 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean diurnal IOP at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }, 
            {
                "measure": "Mean 24-hour IOP at Week 4", 
                "safety_issue": "No", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}